Liver biopsy
ProcedureMeasurement of liver fibrosis
NCT Number: NCT03245606
The main objective is to compare the accuracy of transient elastography taking into account liver steatosis determined by MRI, to liver biopsy for the diagnosis of liver fibrosis ≥F2 in patient with NAFLD.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
CHU d'Angers, Angers, France
No alcoholic fatty liver disease (NAFLD) is induced by an abnormal build up of fat in the liver. It can induce liver damage, namely fibrosis, which leads to cirrhosis and an increased risk of liver cancer. The diagnosis of liver fibrosis is thus critical to identify patients at risk.
Liver biopsy is the gold standard for the diagnosis of liver fibrosis. However this invasive test is expensive and has a significant morbidity.
To avoid this others non invasive test have been developed to assess steatosis and fibrosis of the liver :
The hypothesis driving this study is that by accounting for liver steatosis through the mean of MRI, we could more accurately interpret transient elastography value to accurately diagnose the severity of liver fibrosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Measurement of liver fibrosis
Measurement of liver fibrosis
Measurement of liver fibrosis
Time frame: Day 1
Determination of the fibrosis stage by a double blind reading of liver biopsy by experienced pathologist
Time frame: Day 1
Time frame: Day 1
Time frame: Day 1
Time frame: Day 1
Rennes University Hospital
Other
Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
Acronym: FibroMR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05209100
Body Weight, Digestive System Diseases
Orlando, Florida, United States
View Trial DetailsNCT02267148
Digestive System Diseases, Fatty Liver
Kannapolis, North Carolina, United States
View Trial DetailsNCT05804422
Body Weight, Digestive System Diseases
Kyiv, Ukraine
View Trial DetailsNCT04435054
Body Weight, Digestive System Diseases
Dijon, France
View Trial Details